Japan Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Japan Pharmaceuticals and Healthcare Report

Japan Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Japan Pharmaceuticals and Healthcare Report
Published Aug 20, 2016
127 pages — Published Aug 20, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In July ----, Daiichi Sankyo announced an exclusive agreement with Amgen to commercialise nine biosimilars in Japan. This includes several biosimilars currently in late stage development and includes the biosimilars of adalimumab, bevacizumab and trastuzumab. ...This includes several biosimilars currently in late stage development and includes the biosimilars of adalimumab, bevacizumab and trastuzumab. Under the terms of the agreement, Amgen will be responsible for development and manufacturing while Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialisation in Japan. That same month, local news sources report that Japan-based drugmakers are looking to sell off-patent, established pharmaceutical products in a bid to generate funds to invest into new therapies or business lines. ...July also saw the Ministry of Health, Labour and Welfare announcing an interim report for the implementation of a large scale medical database called MID-NET. Scheduled for FY----, the report specified its use for post marketing surveillance.

...BMI View: Government initiatives in the stem cell sector will continue to play a key role, with the country setting a precedent in its expedited approval process. This in turn encourages investment into sectors that complement regenerative medicine and encourage the formation of research partnerships between local universities and drugmakers. ...BMI View: Government initiatives in the stem cell sector will continue to play a key role, with the country setting a precedent in its expedited approval process. This in turn encourages investment into sectors that complement regenerative medicine and encourage the formation of research partnerships between local universities and drugmakers. Pricing will now be the next key factor that needs to be addressed, with authorities having to maintain financial prudence while rewarding innovation. ...In August ----, Takeda Pharmaceutical disclosed that it will reform its global research organisation by integrating researchers globally in a bid to accelerate innovation.

...� Business Monitor International Ltd Page - Pharmaceutical SWOT Analysis - Continued Ageing population and rising number of chronic and long-term diseases continuing to offer opportunities for makers of innovative products. Current administration s aims to revitalise the Japanese economy will see more support for the biotechnology sector. ...

  
Source:
Document ID
1748-197X
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Japan Pharmaceuticals and Healthcare Report" Aug 20, 2016. Alacra Store. Dec 05, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Japan-Pharmaceuticals-and-Healthcare-Report-2026-116>
  
APA:
Business Monitor International - Industry Reports. (2016). Japan Pharmaceuticals and Healthcare Report Aug 20, 2016. New York, NY: Alacra Store. Retrieved Dec 05, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Japan-Pharmaceuticals-and-Healthcare-Report-2026-116>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.